IMVIONIX acquires U.S. and Canadian rights to BEOVU
IMVIONIX Inc. announced it has acquired exclusive commercial rights to BEOVU (brolucizumab-dbll) in the United States and Canada from Novartis, marking the company's official commercial launch. BEOVU is FDA-approved for treating neovascular (wet) age-related macular degeneration and diabetic macular edema.
Primary source
Company press release (PR Newswire), November 10, 2026
IMVIONIX Acquires U.S. and Canadian Rights to BEOVU® (brolucizumab-dbll), Marking the Company's Official Launch
Read the source: IMVIONIX Acquires U.S. and Canadian Rights to BEOVU® (brolucizumab-dbll), Marking the Company's Official Launch prnewswire.com
Machine-summarized from the source above; not independently reported. How we use automation